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Cardiovascular epidemic and uric acid
The cardiovascular epidemic is a worldwide phenome-
non that accounts for almost 50% of all deaths in indus-
trialized nations, and coronary artery disease (CAD) is one
of the most serious forms of cardiovascular disease (CVD).
Despite the rapid progress made in modern medicine with
regard to controlling the known risk factors for CAD, this
worldwide epidemic still heads the list of national health
concerns, which raises the possibility of the presence of
unknown or underestimated risk factors. Therefore, we
need to identify novel risk factors for CVD, including a
potential therapeutic target. While there is no doubt that
multiple factors play different roles in the development of
CVD, recent studies have revealed the potential role of
hyperuricemia as a novel risk factor. Uric acid is the final
product of purine metabolism in humans, and its level is
determined by dietary intake, rate of cell turn-over in the
body, and renal excretion. Interestingly, primates are the
only species with high uric acid levels, as there has been a
uricase mutation to degrade uric acid into allantoin during
hominoid evolution in contrast to most mammals in which
serum uric acid levels range between 0.5 to 1.5 mg/dL [1].  
Interestingly, uric acid levels have been increasing in
human populations over the last 100 years and, thus,
correlate with the CVD epidemic [2]. Most importantly,
there is astrong evidence from clinical studies and exper-
imental animal models that uric acid is associated with
hypertension and other CVDs. Elevated uric acid is
observed in 89% of new onset essential hypertension in
adolescents and in 25 to 50% of untreated hypertension in
adults [3]. These effects are independent of renal function
or body weight. However, despite solid experimental data
supporting the causative role of uric acid in CVD, most
authorities have viewed hyperuricemia as a secondary
and not causal effect, because hyperuricemia is associated
with other CVD risk factors such as male gender, obesity,
hypertension, renal dysfunction, and diuretic use.
Uric acid and CAD: lessons from previous studies
In this issue of the Korean Journal of Internal Medicine,
Lim et al. demonstrated an association between elevated
uric acid and CAD in 687 patients without a history of
taking diuretics. Although the CAD odds ratio was com-
parable to the uric acid quartile after adjusting for age,
gender, diabetes, hypertension, and metabolic syndrome,
there was a significant association between serum uric
acid and CAD severity. The authors concluded that uric
acid was not an independent risk factor for CAD, but
rather a marker of metabolic syndrome based on multiple
regression analysis results. Recent studies regarding the
role of serum uric acid on CAD risk stratification have
revealed inconsistent results. Hyperuricemia per se was a
significant risk factor for determining the development
or severity of CAD in some studies [4-8], but uric acid was
not an independent factor for CAD and related cardio-
vascular mortality. The Japanese Coronary Artery Disease
Study group demonstrated that elevated serum uric acid
was an independent predictor for cardiovascular events in
patients with severe coronary artery stenosis in their 3
year follow-up [4]. Interestingly, not only high levels of
uric acid, but an increase in uric acid level 6 months after a
coronary event was also associdred with  high cardiovascular
and all-cause mortality. Another study in 2,796 patients
with non-diabetic CAD also showed an association between
serum uric acid and increased cardiovascular events,
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independent of renal function [9]. In contrast, the Genetic
Epidemiology Network of Arteriopathy (GENOA) study
showed that uric acid was associated with the presence
and severity of CAD after adjusting for age and gender,
but not after further adjustment for CVD risk factors [6].
Disparate conclusions regarding the clinical significance
of hyperuricemia in CAD may be related to subject
characteristics, study design, or statistical methodologies.
Interestingly, Lim et al. found that hyperuricemia was
more closely associated with CAD in women than men.
Premenopausal women have a lower uric acid level due to
the uricosuric effect of estrogen; therefore, increased uric
acid levels in women may reflect the presence of other
risk factors resulting in hyperuricemia. The differential
effect of hyperuricemia on CVD according to gender has
already been demonstrated in previous studies but in a
different pattern. A cross-sectional evaluation of the
Atherosclerosis Risk in Communities study population, in
white and black US individuals, showed that serum uric
acid levels were associated with carotid intima-media
thickness in both genders [10]. However, this association
lost its significance in women and was reduced in men
after adjusting for other risk factors. A recent study by
Ishizaka et al. [11] in a large Japanese cohort revealed that
increased uric acid levels were associated with increased
carotid atherosclerosis in men without metabolic syndrome,
but no association was found in either men with metabolic
syndrome or in women. The differential association
between uric acid and CVD in men and women has been
well reviewed in a study by Gagliardi et al. [12]. Further
studies are necessary to investigate the differential impact
of hyperuricemia on the development or aggravation of
CVD in different populations. 
Mechanism of uric acid-induced CVD or metabolic
syndrome
The mechanism by which uric acid may cause CVD has
been explored using cell culture and animal models. It
appears that uric acid must enter the endothelial and
vascular smooth muscle cells via a specific organic anion
exchanger, where it activates a variety of intracellular
signaling molecules involved in inflammation and
proliferation. In the endothelial cells there is a decrease in
nitric oxide levels and an inhibition of endothelial
proliferation, whereas in vascular smooth muscle cells
there is activation of proliferative and inflammatory
pathways [13,14]. Local activation of the renin-angiotensin
system has also been shown [14]. Low nitric oxide may
also have a central role in the induction of insulin resistance,
as insulin requires nitric oxide for its action (by stimulating
blood flow to the skeletal muscle) [15]. 
New studies have also suggested that hyperuricemia
may have a pathogenetic role in obesity-related metabolic
syndrome. Thus, an elevated uric acid level predicted the
development of both obesity and hyperinsulinemia in
normal subjects [15,16], and an elevated uric acid level is
universally present in patients with metabolic syndrome
[17], which was also demonstrated in the study by Lim et
al. Furthermore, recent studies in which rats were fed
fructose to induce metabolic syndrome found that lowering
uric acid levels with allopurinol could significantly prevent
hypertension, hyperinsulinemia, hypertriglyceridemia,
and obesity [16].
Perspectives
Despite the consensus that hyperuricemia is a significant
CVD marker, there are controversies regarding a causative
role for uric acid in CVD and/or metabolic syndrome.
Prospective clinical studies are necessary to investigate
whether a reduction in uric acid levels prevents CVD or
metabolic syndrome. Considering the wealth of basic and
clinical data suggesting a role for uric acid as a vascular
risk factor, and the ease and cost-effectiveness of uric acid-
lowering therapy, the potential causality of hyperuricemia
in CVD and its possible mechanism needs to be further
explored to reduce the cardiovascular epidemic in modern
society.  (Korean J Intern Med 2010;25:18-20)
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